Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Blood Cancer J ; 13(1): 181, 2023 12 08.
Article in English | MEDLINE | ID: mdl-38065967

ABSTRACT

Multiple myeloma (MM) remains incurable despite the availability of novel agents. This multi-center retrospective cohort study used the Canadian Myeloma Research Group Database to describe real-world outcomes of patients withanti-CD38 monoclonal antibody (mAb) refractory MM subsequently treated with standard of care (SoC) regimens. Patients with triple class refractory (TCR) disease (refractory to a proteasome inhibitor, immunomodulatory drug, and anti-CD38 mAb) were examined as a distinct cohort. Overall, 663 patients had disease progression on anti-CD38 mAb therapy, 466 received further treatment (346 with SoC regimens were included, 120 with investigational agents on clinical trial and were excluded). The median age at initiation of subsequent SoC therapy of 67.9 (range 39.6-89.6) years with a median of 3 prior lines (range 1-9). The median PFS and OS from the start of subsequent therapy was 4.6 (95% CI 4.1-5.6) months and 13.3 (95% CI 10.6-16.6) months, respectively. The median PFS and OS of patients with TCR disease (n = 199) was 4.4 (95% CI 3.6-5.3) months and 10.5 (95% CI 8.5-13.8) months. Our results reinforce that real-world patients with relapsed MM, particularly those with TCR disease, have dismal outcomes. There remains an urgent unmet need for the development of and access to effective therapeutics for these patients.


Subject(s)
Antineoplastic Agents , Multiple Myeloma , Humans , Adult , Middle Aged , Aged , Aged, 80 and over , Multiple Myeloma/drug therapy , Retrospective Studies , Canada/epidemiology , Antineoplastic Agents/therapeutic use , Receptors, Antigen, T-Cell , Antineoplastic Combined Chemotherapy Protocols/therapeutic use
2.
J Synchrotron Radiat ; 17(2): 263-7, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20157281

ABSTRACT

Periodontitis is a serious disease that affects up to 50% of an adult population. It is a chronic condition involving inflammation of the periodontal ligament and associated tissues leading to eventual tooth loss. Some evidence suggests that trace metals, especially zinc and copper, may be involved in the onset and severity of periodontitis. Thus we have used synchrotron X-ray fluorescence imaging on cross sections of diseased and healthy teeth using a microbeam to explore the distribution of trace metals in cementum and adhering plaque. The comparison between diseased and healthy teeth indicates that there are elevated levels of zinc, copper and nickel in diseased teeth as opposed to healthy teeth. This preliminary correlation between elevated levels of trace metals in the cementum and plaque of diseased teeth suggests that metals may play a role in the progress of periodontitis.


Subject(s)
Calcium/metabolism , Copper/metabolism , Dental Cementum/chemistry , Periodontitis/metabolism , Zinc/metabolism , Adult , Dental Plaque/chemistry , Female , Humans , Lead/metabolism , Male , Mercury/metabolism , Nickel/metabolism , Spectrometry, X-Ray Emission , Synchrotrons
3.
Curr Oncol ; 27(3): e332-e335, 2020 06.
Article in English | MEDLINE | ID: mdl-32669941

ABSTRACT

The emergence of the covid-19 disease pandemic caused by the 2019 novel coronavirus has required a re-evaluation of treatment practices for clinicians caring for patients with chronic lymphocytic leukemia (cll). The American Society for Hematology (ash) has provided a series of recommendations for the treatment of patients with cll during the pandemic, covering a range of topics, including testing for covid-19, cll treatment initiation and selection, use of immunoglobulin therapy, in-person monitoring, and treatment of patients with cll and covid-19. We summarize the ash recommendations and discuss their applicability as guidelines for the treatment of cll during the covid-19 pandemic in Canada.


Subject(s)
Antineoplastic Agents/therapeutic use , Coronavirus Infections/epidemiology , Immunologic Factors/therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Pneumonia, Viral/epidemiology , Adenine/analogs & derivatives , Ambulatory Care/methods , Appointments and Schedules , Betacoronavirus , COVID-19 , Canada/epidemiology , Coronavirus Infections/complications , Coronavirus Infections/diagnosis , Coronavirus Infections/therapy , Disease Management , Hospitalization , Humans , Immunoglobulins, Intravenous/therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell/complications , Pandemics , Piperidines , Pneumonia, Viral/complications , Pneumonia, Viral/diagnosis , Pneumonia, Viral/therapy , Practice Guidelines as Topic , Pyrazoles/therapeutic use , Pyrimidines/therapeutic use , SARS-CoV-2
4.
J Thromb Haemost ; 6(1): 90-6, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17922807

ABSTRACT

BACKGROUND: The effect of exercise on von Willebrand factor (VWF) and ADAMTS-13 levels in individuals with von Willebrand disease (VWD) has never been reported. OBJECTIVES: The aim was to quantify the effect of a standardized exercise protocol on individuals with type 1 and type 2B VWD. PATIENTS/METHODS: Thirty individuals from three groups (10 controls, 11 with type 1 VWD and 9 with type 2B VWD) completed the Standard Bruce Protocol Treadmill Test. A bleeding questionnaire was administered and blood tests were performed pre- and immediately postexercise. The groups were well matched for age, gender and body mass index (BMI). RESULTS: There was a correlation in all groups between the metabolic equivalents (METS) achieved and the degree of change of VWF and FVIII:C levels (P < 0.002, Pearson's correlation). There was a significant postexercise increase in VWF:Ag, VWF:RCo, FVIII:C and activated VWF levels in both the control group and in the type 2B VWD group, but not in the type 1 VWD group. Specific to the type 2B VWD group was an increase in the percentage of high molecular weight multimers (P = 0.022), a decrease in the mean platelet count compared with the other groups (P < 0.001) and an increase in the ADAMTS-13 level (P = 0.001). CONCLUSIONS: There are significant differences in the effects of exercise on individuals with type 1 and type 2B VWD compared with controls. Further clinical studies are necessary to evaluate exercise as a therapeutic option in VWD.


Subject(s)
ADAM Proteins/blood , Exercise/physiology , von Willebrand Diseases/blood , von Willebrand Diseases/therapy , von Willebrand Factor/analysis , ADAMTS13 Protein , Case-Control Studies , Factor VIII/analysis , Humans , Platelet Count , von Willebrand Diseases/classification
5.
Bone Marrow Transplant ; 40(4): 369-72, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17589533

ABSTRACT

The role of allogeneic stem cell transplantation (SCT) in Waldenstrom's macroglobulinaemia (WM) is not yet clear, as published data on allogeneic SCT in WM are limited. We present a retrospective study of allogeneic SCT in five patients with WM. Median age was 56 years (range 40-60 years). All patients were heavily pretreated. Conditioning therapy with busulphan and cyclophosphamide was used for all patients and all were given cyclosporine and methotrexate for graft-versus-host disease prophylaxis. With a median follow-up of 32 months (range 2-43), all except one are alive and disease free. Progressive, delayed decline in serum IgM levels were noted in all the patients, suggesting an active graft-versus-Waldenstrom's effect. With the limited available data, it appears that allogeneic SCT is a useful treatment option for advanced WM.


Subject(s)
Graft vs Tumor Effect , Hematopoietic Stem Cell Transplantation/methods , Waldenstrom Macroglobulinemia/therapy , Adult , Disease-Free Survival , Female , Humans , Male , Middle Aged , Retrospective Studies , Transplantation, Homologous
7.
Hematology ; 13(5): 261-6, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18854087

ABSTRACT

Up to 60% of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) do not respond to second-line (salvage) chemotherapy and hence are not offered autologous hematopoietic cell transplantation (AHCT). The utility of further salvage chemotherapy in an attempt to proceed with AHCT remains undefined. The authors reviewed 201 patients with DLBCL relapsed/refractory to anthracycline-based chemotherapy who received first-line salvage chemotherapy containing cis-platinum. Of the 120 non-responders to first-line platinum-based salvage chemotherapy, 73 received second-line salvage chemotherapy. The response rate to second-line salvage chemotherapy was 14%. Factors predicting lack of response were progression on primary therapy (p = 0.007), abnormal lactate dehydrogenase findings (p = 0.0027) and tumor bulk (p = 0.013) at second progression. Eight patients who responded received AHCT and appeared to have comparable survival to those transplanted after one salvage regimen. The authors conclude that the utility of second-line salvage chemotherapy is low, and that it is best reserved for patients demonstrating initial anthracycline sensitivity and low tumor burden.


Subject(s)
Antineoplastic Agents/therapeutic use , Lymphoma, Large B-Cell, Diffuse/drug therapy , Salvage Therapy/methods , Adult , Aged , Anthracyclines/therapeutic use , Cisplatin/therapeutic use , Female , Humans , Male , Middle Aged , Prognosis , Retrospective Studies , Treatment Failure , Treatment Outcome , Young Adult
8.
Bone Marrow Transplant ; 42(11): 733-7, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18711349

ABSTRACT

Peripheral blood hematopoietic progenitor cells (PBHC) are the standard source of support for high-dose chemotherapy because of faster recovery of marrow function. Unfortunately, a proportion of patients are unable to mobilize adequate progenitors to proceed to autologous hematopoietic cell transplant (AHCT). Granulocyte-CSF-stimulated BM-derived hematopoietic progenitor cells (BMHC) may circumvent this problem. From 1999 to 2006, 52 patients (cases) with AML, Hodgkin (HL) or non-Hodgkin's lymphoma (NHL) in whom PBHC mobilization failed underwent a G-CSF-stimulated bone marrow harvest and proceeded to AHCT. Their outcome was compared with 422 patients (controls) with AML, HL and NHL undergoing AHCT using only PBHC. Twenty-three patients received BMHC alone and 29 patients received a combination of PBHC and BMHC. Median engraftment time for neutrophils (>0.5 x 10(9)/l) and platelets (>20 x 10(9)/l) were 14 and 27 days, but significantly longer when compared with controls (11 days, 11 days, P<0.0001). Patients receiving both PBHC and BMHC had faster engraftment, when compared with those receiving BMHC alone (P<0.001). In conclusion, performing an AHCT using G-CSF-stimulated BMHC in patients failing PBHC collection is feasible with faster engraftment seen in patients receiving both BMHC and PBHC over BMHC alone.


Subject(s)
Bone Marrow Transplantation/methods , Granulocyte Colony-Stimulating Factor/metabolism , Stem Cells/cytology , Adult , Aged , Female , Hematologic Neoplasms/therapy , Hematopoietic Stem Cell Mobilization/methods , Hematopoietic Stem Cells/cytology , Humans , Male , Middle Aged , Neutrophils/cytology , Time Factors , Treatment Outcome
9.
J Can Dent Assoc ; 64(4): 269-75, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9594465

ABSTRACT

Scaling and root planing (S&RP) are regarded as the main modalities for treating periodontal disease. The goal of these treatments is to arrest the disease process, maintain a healthy periodontium and preserve the dentition. As prevention becomes a larger component of everyday dental practice, dentists are performing S&RP more often as part of their periodontal maintenance programs. Therefore, it is essential for dentists to know the latest S&RP techniques and methods. This paper reviews the current knowledge and experiences related to mechanical non-surgical periodontal therapy and focuses on the types of S&RP instruments that are available, their advantages and disadvantages, their efficacy in debridement, and their effects on the hard tissues of the oral cavity.


Subject(s)
Dental High-Speed Equipment , Dental Instruments , Dental Scaling/instrumentation , Dental Cementum/microbiology , Dental Cementum/surgery , Equipment Design , Humans , Root Planing/instrumentation , Sonication/instrumentation , Ultrasonic Therapy/instrumentation
14.
Dent J ; 44(1): 26-7, 1978 Jan.
Article in English | MEDLINE | ID: mdl-272989
15.
J Can Dent Assoc ; 57(1): 42-5, 1991 Jan.
Article in English | MEDLINE | ID: mdl-2009457
SELECTION OF CITATIONS
SEARCH DETAIL